By Colin Kellaher
Zynerba Pharmaceuticals shares nearly quadrupled in early trading Monday after the company agreed to be acquired by Harmony Biosciences at a rich premium.
Harmony said it could pay up to $200 million, or $3.65 a share, for Zynerba, nearly 11 times Friday’s closing price of 33.9 cents.
The…
Read the full article here
Unlock the White House Watch newsletter for freeYour guide to what the…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
One of Dr Mo Sarhan’s patients was experiencing intense cravings for opioids…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
